buyWeak
Franklin Stuart Friedman bought $139k of DCPH
director at Deciphera Pharmaceuticals, Inc.. 10,000 shares at an average of $13.88, traded Jun 8, 2023, filed Jun 12, 2023.
Conviction score
34Value
$139k
10,000 shares
Holdings after
10,000
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +11Trade size$139k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-036244, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 8, 2023 | POpen-market purchase Common Stock | +10,000 | $13.88 | $139k | 10,000 | Jun 12, 2023 |
Related signals
Other insiders at Deciphera Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Deciphera Pharmaceuticals, Inc. | Jama Pitman SVP, Chief Development Officer | $35k 2,267 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $41k 2,615 shares | -2% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $35k 2,267 shares | -4% | |
| 43Moderate | Deciphera Pharmaceuticals, Inc. | Thomas Patrick Kelly Chief Financial Officer | $47k 3,010 shares | -4% | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $23k 1,624 shares | -3% | |
| 43Moderate | Deciphera Pharmaceuticals, Inc. | Thomas Patrick Kelly Chief Financial Officer | $35k 2,435 shares | -4% | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | Jama Pitman SVP, Chief Development Officer | $23k 1,624 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $35k 2,435 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $43k 2,792 shares | -3% | |
| 35Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $27k 1,727 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.